Implementation of the Windsor Framework: UK's Pharmaceutical Regulation Unified

Effective January 1, 2025, the Windsor Framework agreement reached in February 2023 between the UK and the EU has been fully implemented. The new regulatory arrangements replace the Northern Ireland Protocol (“the Protocol”), making the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) the sole drug approval authority across the entire UK, including Northern Ireland. The European Medicines Agency (EMA) is no longer directly involved, ending the regulatory confusion caused by Brexit and ensuring stability and unification in the UK pharmaceutical market. The new rules apply only to human medicines and do not cover medical devices.

Resolving Supply Issues for Medicines in Northern Ireland

Under the initial Brexit agreement, the EU remained responsible for regulating medicines in Northern Ireland. However, in practice, this arrangement frequently triggered trade friction and heightened concerns about drug shortages. As required by the Protocol, new drugs approved by the MHRA were not automatically available in Northern Ireland and required approval from the EMA and the European Commission (EC) under the EU Centralised Procedure.

Additionally, the EU’s Falsified Medicines Directive (FMD) imposed safety requirements for packaging, barcodes, and scanning in Northern Ireland but not on Great Britain, further complicating and increasing the cost of supply chains. Under an interim agreement reached in April 2022, drugs could circulate within Great Britain (GB) without removing the FMD unique identifier from packaging until the end of 2024. However, after the transition period, differing licensing, batch approval, and labeling requirements were expected to increase supplier costs, jeopardizing Northern Ireland's drug supply security.

The Windsor Framework addresses these issues by delineating the applicability of EU rules in Northern Ireland, granting the UK greater autonomy in regulating medicines in the region. Northern Ireland no longer needs to fully comply with EU regulations.

New Regulatory Changes under the Windsor Framework

1. Authorization and Licensing: Drug licenses granted via the EU Centralised Procedure are no longer valid in Northern Ireland.
2. EU FMD Requirements: The EU Falsified Medicines Directive no longer applies to medicines in Northern Ireland.
3. Unified Labeling and Packaging: All medicines marketed in the UK must bear a “UK Only” label, covering General Sales List (GSL), Pharmacy-only (P), and Prescription-only Medicines (POM). Until June 30, 2025, new labels may appear as stickers, but after this date, the label must be printed directly on the packaging. This requirement prevents UK products from entering the EU via Northern Ireland but does not affect exports compliant with destination-country laws. Products already on the market can circulate in permitted regions until their expiration date, but joint EU/UK packaging will no longer be allowed.
4. License Categorization: Previously, licenses were geographically categorized into UK-wide (PL prefix), Great Britain-only (PLGB), and Northern Ireland-only (PLNI). UK-wide and Northern Ireland licenses were subject to EU law. Under the new arrangements, most drugs will receive UK-wide licenses. Existing PLGB licenses will automatically convert to UK-wide licenses starting in 2025. The new framework divides medicines into two categories:
   • Category 1: Products authorized across the UK under UK law with pharmacovigilance adhering solely to UK requirements.
   • Category 2: Products governed by EU law (excluding those requiring Centralised Procedure authorization) with pharmacovigilance adhering to both UK and EU requirements.

   New applications submitted from 2025 onwards must specify the product’s category, which will remain fixed for its lifecycle.

Logistics: Dual-Channel Mechanism

The Windsor Framework introduces a dual-channel system to balance the UK's sovereignty and the EU's single market integrity:

• Green Channel: Applies to goods from Great Britain intended exclusively for sale in Northern Ireland, exempting them from customs and paperwork.
• Red Channel: Applies to goods transiting Northern Ireland to Ireland or the EU, maintaining necessary regulatory and customs checks.

Conclusion

The Windsor Framework establishes a long-term solution for the supply of medicines to Northern Ireland, promoting trade flow and reducing the likelihood of a "hard border" between Northern Ireland and Ireland. Given the divergence between UK and EU pharmaceutical regulatory systems, the new rules require Chinese pharmaceutical companies expanding into the European market to closely monitor regulatory changes and make necessary compliance adjustments. This includes adhering to new review processes, labeling requirements, and packaging standards. Companies supplying both the UK and EU markets should evaluate the cost-efficiency of different channels and optimize their supply chains to ensure smooth distribution and competitiveness across different regions.